Filing summary
Entity and period: The supplied filing is Synta Pharmaceuticals Corp.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 12, 2015. It is not a filing for Madrigal Pharmaceuticals, Inc.; the company name in the request metadata does not match the filing. The annual report includes unaudited fourth-quarter results.
Business context
Synta was a clinical-stage oncology biopharmaceutical company with no approved products or product sales. Its lead candidate, ganetespib, was being studied in several cancer indications, including a pivotal Phase 3 non-small cell lung cancer (NSCLC) trial. Other programs included the preclinical Hsp90 drug-conjugate platform, led by STA-12-8666, and clinical-stage elesclomol. In 2014, Synta licensed out its CRACM and IL-12/23 programs and redirected resources toward oncology.
Financial results and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $68.2 million | $71.9 million |
| General and administrative expense | $15.7 million | $15.7 million |
| Total operating expenses | $84.0 million | $87.6 million |
| Net loss | $86.2 million | $90.2 million |
| Basic and diluted loss per share | $0.87 | $1.27 |
| Cash, cash equivalents and marketable securities at year-end | $97.7 million | $91.5 million |
| Working capital at year-end | $68.5 million | $60.0 million |
| Term loans at year-end, current and long-term | $13.8 million | $23.3 million |
| Operating cash used | $78.9 million | $77.4 million |
There was no product revenue; the company also reported no grant revenue in 2014. Net loss narrowed by about 4% year over year, while operating cash use increased modestly. Year-end cash resources rose despite operating cash burn, mainly due to equity financing. The company sold shares through at-the-market offerings and a registered direct offering, raising approximately $94.0 million in net proceeds in 2014; common shares outstanding increased from 85.2 million to 109.1 million. No profit margins are meaningful given the absence of revenue and continuing losses.
At December 31, 2014, current assets were $99.3 million and current liabilities were $30.9 million. The company said its $97.7 million in cash resources was expected to fund operations at least through the end of 2015, assuming no new partnerships, equity financing, or further ATM sales. This was management’s estimate, not a guarantee. Scheduled 2015 term-loan principal payments were $9.2 million; debt carried covenants and security interests. Operating and R&D contract obligations were substantial, including $56.7 million in R&D contracts listed in contractual obligations.
Material changes and operating developments
- R&D expense fell 5% from 2013. Ganetespib spending declined to $56.8 million from $64.5 million, as trial wind-downs and other reductions outweighed higher GALAXY-2 and I-SPY 2 costs. Early-stage program expense rose with investment in the HDC program.
- G&A expense was broadly unchanged. 2014 included approximately $2.0 million of costs related to the former CEO’s separation and about $0.4 million of new CEO sign-on and relocation costs.
- Interest expense decreased to $2.2 million from $2.6 million, reflecting scheduled debt repayment. Term-loan principal declined, with GECC payments amortizing over 30 months beginning January 2014.
- Ganetespib’s GALAXY-1 Phase 2b results supported selection of patients diagnosed with advanced disease more than six months earlier for the pivotal GALAXY-2 study. In that subgroup, reported median overall survival was 11.0 months with ganetespib plus docetaxel versus 7.4 months with docetaxel; these Phase 2 results do not establish Phase 3 success.
- In March 2015, Synta reported 500 patients enrolled in GALAXY-2 and expected the first interim overall-survival analysis in the second half of 2015; further interim and final analyses were projected for 2016.
- STA-12-8666 entered IND-enabling studies in the first quarter of 2015. The company expected to submit an IND by the first quarter of 2016 and nominate another HDC candidate in the first half of 2016.
Outlook, risks and unusual items
In February 2015, management outlined a strategy to concentrate resources on ganetespib and selected HDC candidates, seek potential partnerships, and improve operating efficiency. Subject to positive GALAXY-2 interim results and regulatory feedback, Synta planned to seek North American and European approval for ganetespib in NSCLC in 2016. The company also announced a workforce reduction of approximately 20%; together with 2014 reductions, headcount had fallen from 133 at the start of 2014 to 90 in February 2015.
- Clinical and regulatory outcomes remain uncertain. The company had no approved product, had accumulated a $637.6 million deficit, expected continuing losses, and warned that additional capital might be needed sooner than planned.
- Ganetespib had QTc interval prolongation in a healthy-volunteer study. The filing described the clinical significance as uncertain and said enhanced ECG monitoring was in place, including in GALAXY-2.
- Ganetespib and elesclomol depend on third-party manufacturers; Synta also relies on external organizations for clinical trials. Manufacturing disruption, enrollment delays, adverse events, or inconclusive results could delay development.
- Management stated that most prior elesclomol trials were negative or inconclusive; the ongoing ovarian cancer study remained a potential but unproven opportunity.
- Funding through equity sales caused substantial dilution. GECC debt included restrictive covenants and a potential springing security interest in intellectual property in specified circumstances.
- The company reported no material legal proceedings. The independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting.
Investor facts to verify
- Confirm the issuer identity: this is Synta Pharmaceuticals Corp., not Madrigal Pharmaceuticals, Inc.
- Review subsequent GALAXY-2 interim and final results, including statistical significance, safety, and any regulatory feedback.
- Track cash burn, financing activity, share-count dilution, debt repayment and compliance with loan covenants against the stated runway estimate.
- Verify timing and progress of the STA-12-8666 IND and the next HDC candidate; preclinical findings are not clinical proof.
- Assess the QTc monitoring results, manufacturing readiness and whether any development or regulatory milestones have changed.